kuvura kanseri y'ibihaha

Iterambere rya vuba muri kuvura kanseri y'ibihaha tanga ubuzima bwiza bwo kubaho no kubaho neza kubarwayi. Harimo ubuvuzi bugenewe, immunotherapie, hamwe nubuhanga buhanitse bwo kubaga. Gusobanukirwa nuburyo bushobora guha abarwayi nimiryango yabo gufata ibyemezo byuzuye hamwe nabashinzwe ubuzima. Iyi ngingo itanga incamake yuburyo bugezweho hamwe nuburyo bwo kuvura buboneka.Kumva Kanseri yibihaha no gukenera imiti mishya Kanseri yibihaha iracyari ikibazo gikomeye cyubuzima ku isi. Ni ngombwa kumva ubwoko butandukanye bwa kanseri y'ibihaha nibintu bigira uruhare mu iterambere ryayo. Ubuvuzi gakondo nka chimiotherapie hamwe nubuvuzi bwimirasire bufite aho bugarukira, bishimangira ko byihutirwa kuvura kanseri y'ibihaha ingamba. Ubwoko bwa Kanseri y'ibihaha Ubwoko bubiri bw'ingenzi ni: Kanseri y'ibihaha itari ntoya (NSCLC): Ubu ni bwo bwoko bukunze kugaragara, bingana na 80-85% by'abanduye kanseri y'ibihaha. Ubwoko butandukanye burimo adenocarcinoma, kanseri y'udukoko twa kanseri, na kanseri nini. Kanseri y'ibihaha ntoya (SCLC): Ubu bwoko ntibusanzwe kandi bukunda gukura no gukwirakwira vuba kurusha NSCLC.Iterambere muri Targeted Therapy ya Kanseri yibihahaTargeted therapy ni a kuvura kanseri y'ibihaha yibanda kuri molekile zihariye zigira uruhare mu mikurire ya kanseri no kubaho. Bitandukanye na chimiotherapie yibasira ingirabuzimafatizo zose zigabanya vuba, imiti igamije kwica guhitamo kanseri ya kanseri mugihe irinze izifite ubuzima bwiza. Ibi akenshi biganisha ku ngaruka nkeya.Ibisanzwe Byagenewe Ubuvuzi hamwe nintego zaboIbintu bitandukanye bivura ubu byemewe gukoreshwa muburyo bumwe bwa NSCLC. Ubu buryo bwo kuvura bukunze kwibasira ihinduka ryimiterere muri gen nka EGFR, ALK, ROS1, BRAF, MET, na NTRK. Intego Urugero Ibiyobyabwenge Byihariye Ubwoko bwa NSCLC Ubwoko bwa EGFR Osimertinib (Tagrisso) NSCLC hamwe na mutation ya EGFR ALK Alectinib (Alecensa) NSCLC hamwe na ALK itunganijwe ROS1 Entrectinib (Rozlytrek) NSCLC hamwe na ROS1 itunganijwe Source: Umuryango w'AbanyamerikaUruhare rwo Kwipimisha Biomarker Mbere yo gutangira kuvura intego, gupima biomarker ni ngombwa. Iri suzuma ririmo gusesengura icyitegererezo cy’ibibyimba by’umurwayi kugira ngo hamenyekane ihinduka ry’imiterere yihariye ya poroteyine cyangwa poroteyine zidasanzwe. Ibisubizo byo gupima biomarker bifasha abaganga kumenya niba umurwayi ashobora kungukirwa nubuvuzi bwihariye. Uwiteka Shandong Baofa Ikigo Cyubushakashatsi Kanseri ashimangira akamaro ko kwisuzumisha neza kugirango bivurwe neza.Immunotherapy: Gukoresha Sisitemu Immune Kurwanya Kanseri Y ibihahaImmunotherapy yerekana irindi terambere rikomeye muri kuvura kanseri y'ibihaha. Ubu buryo bukora mu gukangurira umubiri indwara z'umubiri kumenya no gutera kanseri. Imiti ikingira indwara, nk'ibikoresho byo kugenzura, ibuza poroteyine zibuza umubiri kwirinda indwara ya kanseri. Ubwoko bw'imiti ya Immunotherapy imiti ya kanseri y'ibihahaImiti ikingira indwara ikoreshwa mu kuvura kanseri y'ibihaha harimo: Inzitizi za PD-1: Pembrolizumab (Keytruda), Nivolumab (Opdivo) Inzitizi za PD-L1: Atezolizumab (Tecentriq), Durvalumab (Imfinzi) CTLA-4 inhibitor: Ipilimumab (Yervoy) (ikunze gukoreshwa ifatanije na PD-1 inhibitor) Ninde mukandida wa Immunotherapie? Icyemezo cyo gukoresha immunotherapi giterwa nibintu byinshi, harimo ubwoko nicyiciro cya kanseri yibihaha, ubuzima bwumurwayi muri rusange, hamwe nurwego rwa PD-L1 mumagambo yibibyimba. PD-L1 ni poroteyine ishobora gufasha ingirabuzimafatizo za kanseri kwirinda ubudahangarwa bw'umubiri. Abarwayi bafite imvugo ndende ya PD-L1 birashoboka cyane ko bitabira immunotherapy. Umuganga wa oncologue azasuzuma yitonze buri murwayi kugirango amenye niba immunotherapie ikwiye. kuvura kanseri y'ibihaha, cyane cyane icyiciro cya mbere NSCLC. Iterambere mu buhanga bwo kubaga ryatumye habaho uburyo butagaragara bwo gutera no kugera ku musaruro ushimishije.Minimally Invasive SurgeryMinimasi yibasiye cyane, nka videwo ifashwa na videwo yo kubaga thoracoscopique (VATS) no kubaga robot, bituma abaganga bakuramo ibibyimba binyuze mu bice bito. Ubu buhanga butanga ibyiza byinshi kubagwa gakondo, harimo ububabare buke, kumara igihe gito ibitaro, hamwe nigihe cyo gukira vuba.Stereotactic Body Radiotherapy (SBRT) Nubwo atari kubagwa cyane, SBRT nuburyo busobanutse neza bwo kuvura imirasire ishobora gukoreshwa mu kuvura kanseri yibihaha hakiri kare kubarwayi badakwiriye kubakirwa kubagwa. SBRT itanga urugero rwinshi rwimirasire yibibyimba mugihe hagabanijwe guhura ningirangingo nzima zikikije.Guhuza imiti kubisubizo byiza Mubihe byinshi, uburyo bwiza bwo kugera kuvura kanseri y'ibihaha bikubiyemo guhuza imiti itandukanye. Kurugero, abarwayi barashobora guhabwa chimiotherapie ikurikirwa no kubagwa, cyangwa kuvura intego hamwe no gukingira indwara. Guhuza uburyo bwihariye bwo kuvura bizaterwa nuburwayi bwumuntu ku giti cye. Akamaro k’ibigeragezo by’amavuriroIbizamini bya kliniki bigira uruhare runini mu iterambere kuvura kanseri y'ibihaha ingamba. Ibi bigeragezo bisuzuma umutekano nuburyo bwiza bwibiyobyabwenge nuburyo bwo kuvura. Abarwayi bitabira ibizamini byamavuriro barashobora kubona uburyo bwo kuvura butaraboneka henshi. Tekereza kuganira kumahitamo yo kwa muganga hamwe na oncologue wawe. Amakuru yerekeye inzira zamavuriro ajyanye nubushakashatsi bwa kanseri murayasanga kuri Shandong Baofa Ikigo Cyubushakashatsi Kanseri urubuga. Kubana na Kanseri y'ibihaha: Inkunga n'umutungoIsuzuma rya kanseri y'ibihaha rirashobora kuba ryinshi. Ni ngombwa gushaka inkunga kubashinzwe ubuzima, umuryango, inshuti, hamwe nitsinda ryunganira. Amashyirahamwe menshi atanga ibikoresho na serivisi bifasha abarwayi nimiryango yabo guhangana ningorane zo kubana na kanseri yibihaha.UmwanzuroIterambere rikomeye ryatewe muri kuvura kanseri y'ibihaha mu myaka yashize. Ubuvuzi bugenewe, immunotherapie, hamwe nubuhanga buhanitse bwo kubaga butanga ibyiringiro bishya kubarwayi ba kanseri yibihaha. Mugukomeza kumenyeshwa ibyagezweho no gukorana neza nitsinda ryabo ryita ku buzima, abarwayi barashobora gufata ibyemezo byuzuye kandi bikongerera amahirwe yo kubaho no kubaho neza.